Stereotaxis Inc (STXS) Stock Price, Quote & News

Company Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed t...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 314 678 6100

Website: www.stereotaxis.com

Address:

710 North Tucker Boulevard, Suite 110, Saint Louis, United States

MarketBeat May. 16 at 2:05 AM

https://marketbeat.com/a/8657210/ $STXS Stereotaxis Q1 Earnings Call Highlights

0 · Reply

no_ego May. 15 at 7:56 PM

$STXS may take a couple of years for company to fix it's issues

1 · Reply

no_ego May. 15 at 7:55 PM

$STXS should fly on Monday! Maybe hit 1.90

0 · Reply

alexpitti May. 15 at 2:59 PM

Triple ouch $STXS $ABEO $DCTH

2 · Reply

no_ego May. 15 at 1:52 PM

$STXS 1.95 is a gift! Sell!

0 · Reply

no_ego May. 15 at 12:27 PM

$STXS last chance to get out above 1.90. Don’t gamble!

2 · Reply

brunoq14 May. 15 at 4:57 AM

$STXS AI says that the current consensus for Q2 revenue is about $9.6M, a substantial rebound from Q1's $6.3M. That would validate the company's bullish forecast for the next two quarters.

1 · Reply

_Not_Sure_ May. 14 at 6:14 PM

$STXS what am I missing? Why the price action today vs. yesterday???

2 · Reply

Eddypgil May. 14 at 2:37 PM

$STXS seems like a great entry point. At very least buy some shares a put them away.

0 · Reply

Georges8792 May. 14 at 6:54 AM

$STXS still dont know how we gonna pay for robo … is David making trips to Vegas trying to win 50 million 😂😂😂

4 · Reply

Stereotaxis price target lowered to $3.50 from $4 at Piper Sandler

JNJ

May 12, 2026, 4:30 PM EDT - 3 days ago

Stereotaxis Earnings Call Transcript: Q1 2026

May 12, 2026, 4:06 PM EDT - 3 days ago

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Apr 22, 2026, 7:58 AM EDT - 23 days ago

Stereotaxis Announces First MAGiC Procedures in the United States

Apr 21, 2026, 9:01 AM EDT - 24 days ago

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

Apr 15, 2026, 9:00 AM EDT - 4 weeks ago

Stereotaxis Transcript: M&A announcement

2026-04-15T11:12:19.000Z - 4 weeks ago

Stereotaxis to acquire Robocath, terms undisclosed

Apr 15, 2026, 7:00 AM EDT - 4 weeks ago

Stereotaxis Announces Definitive Agreement to Acquire Robocath

2026-04-06T12:40:34.000Z - 5 weeks ago

Stereotaxis receives FDA clearance for Synchrony system

Apr 6, 2026, 8:06 AM EDT - 5 weeks ago

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

2026-03-13T20:30:19.000Z - 2 months ago

Stereotaxis files $100M mixed securities shelf

2026-03-13T19:35:41.000Z - 2 months ago

Stereotaxis management to meet virtually with BTIG

Mar 9, 2026, 4:30 PM EDT - 2 months ago

Stereotaxis Earnings Call Transcript: Q4 2025

2026-03-09T20:05:19.000Z - 2 months ago

Stereotaxis reports Q4 EPS (6c), consensus (6c)

2026-03-09T20:05:10.000Z - 2 months ago

Stereotaxis sees FY26 revenue up double digits

Mar 9, 2026, 4:01 PM EDT - 2 months ago

Stereotaxis Reports 2025 Full Year Financial Results

Feb 12, 2026, 9:00 AM EST - 3 months ago

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

2026-02-09T13:37:08.000Z - 3 months ago

Stereotaxis announces launch of electrophysiology program at Klinikum Furth

Feb 9, 2026, 8:06 AM EST - 3 months ago

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

2026-01-06T13:39:16.000Z - 4 months ago

Stereotaxis reports FDA approval for MAGiC Ablation Catheter

Jan 6, 2026, 8:01 AM EST - 4 months ago

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

2025-12-16T09:40:34.000Z - 5 months ago

Stereotaxis initiated with an Outperform at Citizens

Nov 24, 2025, 8:58 AM EST - 6 months ago

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 11, 2025, 4:30 PM EST - 6 months ago

Stereotaxis Earnings Call Transcript: Q3 2025

2025-11-11T21:05:25.000Z - 6 months ago

Stereotaxis reports Q3 EPS (7c), consensus (6c)

Nov 11, 2025, 4:01 PM EST - 6 months ago

Stereotaxis Reports 2025 Third Quarter Financial Results

2025-11-10T22:01:01.000Z - 6 months ago

Stereotaxis announces FDA clearance for GenesisX

Nov 10, 2025, 4:05 PM EST - 6 months ago

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

2025-11-05T09:25:11.000Z - 6 months ago

Stereotaxis resumed with a Buy at Roth Capital

Oct 21, 2025, 9:00 AM EDT - 7 months ago

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

2025-10-15T11:35:16.000Z - 7 months ago

Stereotaxis announces EU launch, 510k submission for Synchrony system

Oct 15, 2025, 7:32 AM EDT - 7 months ago

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

2025-10-13T11:46:17.000Z - 7 months ago

Stereotaxis, CardioFocus collaborate to advance robotic PFA technology

Oct 13, 2025, 7:34 AM EDT - 7 months ago

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias

2025-09-22T12:00:15.000Z - 8 months ago

Stereotaxis announces procedures using Genesis at Erasmus Medical Center

Sep 22, 2025, 7:56 AM EDT - 8 months ago

Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

2025-09-02T12:40:31.000Z - 9 months ago

Stereotaxis announces completion of procedure using MAGiC Sweep

Sep 2, 2025, 8:08 AM EDT - 9 months ago

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

Sep 2, 2025, 7:51 AM EDT - 9 months ago

Stereotaxis to Present at Upcoming Investor Conferences

Aug 28, 2025, 7:47 AM EDT - 9 months ago

Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Stereotaxis Earnings Call Transcript: Q2 2025

2025-08-07T20:21:40.000Z - 10 months ago

Stereotaxis reports Q2 EPS (5c), consensus (6c)

Aug 7, 2025, 4:01 PM EDT - 10 months ago

Stereotaxis Reports 2025 Second Quarter Financial Results

2025-07-28T11:55:43.000Z - 10 months ago

Stereotaxis receives FDA clearance for MAGiC Sweep catheter

Jul 28, 2025, 7:48 AM EDT - 10 months ago

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Jul 23, 2025, 8:00 AM EDT - 10 months ago

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 17, 2025, 8:32 AM EDT - 10 months ago

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

Jul 1, 2025, 9:00 AM EDT - 11 months ago

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

May 12, 2025, 4:30 PM EDT - 1 year ago

Stereotaxis Earnings Call Transcript: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Stereotaxis Reports 2025 First Quarter Financial Results

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

Mar 19, 2025, 8:01 AM EDT - 1 year ago

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Mar 10, 2025, 8:02 AM EDT - 1 year ago

Stereotaxis to Present at 37th Annual Roth Conference

Mar 3, 2025, 8:30 AM EST - 1 year ago

Stereotaxis Earnings Call Transcript: Q4 2024

Mar 3, 2025, 7:32 AM EST - 1 year ago

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Mar 3, 2025, 7:31 AM EST - 1 year ago

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

Mar 3, 2025, 7:30 AM EST - 1 year ago

Stereotaxis Reports 2024 Full Year Financial Results

Feb 25, 2025, 8:03 AM EST - 1 year ago

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Jan 30, 2025, 8:09 AM EST - 1 year ago

Stereotaxis Announces First GenesisX Robotic System Order

Jan 27, 2025, 8:00 AM EST - 1 year ago

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

Jan 14, 2025, 7:21 AM EST - 1 year ago

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

Dec 9, 2024, 7:25 AM EST - 1 year ago

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

Dec 2, 2024, 8:45 AM EST - 1 year ago

Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

Nov 26, 2024, 8:28 AM EST - 1 year ago

Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 8:21 AM EST - 1 year ago

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

Nov 20, 2024, 8:18 AM EST - 1 year ago

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Nov 11, 2024, 4:30 PM EST - 1 year ago

Stereotaxis Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:02 PM EST - 1 year ago

Stereotaxis Reports 2024 Third Quarter Financial Results

Oct 21, 2024, 8:41 AM EDT - 1 year ago

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Sep 3, 2024, 8:53 AM EDT - 1 year ago

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Stereotaxis Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Stereotaxis Reports 2024 Second Quarter Financial Results

Aug 12, 2024, 4:03 PM EDT - 1 year ago

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

Jul 22, 2024, 4:05 PM EDT - 1 year ago

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

Jul 18, 2024, 4:13 PM EDT - 1 year ago

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

May 29, 2024, 8:25 AM EDT - 2 years ago

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

MarketBeat May. 16 at 2:05 AM

https://marketbeat.com/a/8657210/ $STXS Stereotaxis Q1 Earnings Call Highlights

0 · Reply

no_ego May. 15 at 7:56 PM

$STXS may take a couple of years for company to fix it's issues

1 · Reply

no_ego May. 15 at 7:55 PM

$STXS should fly on Monday! Maybe hit 1.90

0 · Reply

alexpitti May. 15 at 2:59 PM

Triple ouch $STXS $ABEO $DCTH

2 · Reply

no_ego May. 15 at 1:52 PM

$STXS 1.95 is a gift! Sell!

0 · Reply

no_ego May. 15 at 12:27 PM

$STXS last chance to get out above 1.90. Don’t gamble!

2 · Reply

brunoq14 May. 15 at 4:57 AM

$STXS AI says that the current consensus for Q2 revenue is about $9.6M, a substantial rebound from Q1's $6.3M. That would validate the company's bullish forecast for the next two quarters.

1 · Reply

_Not_Sure_ May. 14 at 6:14 PM

$STXS what am I missing? Why the price action today vs. yesterday???

2 · Reply

Eddypgil May. 14 at 2:37 PM

$STXS seems like a great entry point. At very least buy some shares a put them away.

0 · Reply

Georges8792 May. 14 at 6:54 AM

$STXS still dont know how we gonna pay for robo … is David making trips to Vegas trying to win 50 million 😂😂😂

4 · Reply

SuperGreenToday May. 13 at 10:01 PM

$STXS Share Price: $1.86 Contract Selected: Nov 20, 2026 $2.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.14 – $0.17 Potential Upside: 58% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

DecoderRing May. 13 at 12:14 PM

$STXS reading through the transcript got interesting when: David made sure that when he was talking about X-ray manufacturer partnerships, he then referenced the automation project as a different "large industry partner". This removes Siemens/Philips and GE (Xray imaging infratstructure) - which leaves Abbott (EP/device ecosystem). Abbott publicly lists both Stereotaxis and Volta inside its EnSite : Volta = AI arrhythmia targeting Stereotaxis = robotic catheter navigation Abbott = mapping / data / workflow layer So on my read, its an ongoing collaboration, probably still under NDA but at least advanced enough at this point to be included in strategic discussions. Read up more on Ensite X LiveSync to see how its not just a catheter compatibility layer but more a software/workflow layer. The story is now more an AI play with decision support via Volta, navigation with Stereotaxis and mapping/data handled by Ensite X. If this comes together, the story is much much larger than we realize

2 · Reply

Daquanladariusblackman3 May. 13 at 12:12 PM

$STXS David is an idiot who has no idea what he’s doin and doesn’t know how to run a company, Alex pitti is a loser who duped you all with buzzwords and probably has a short position, and this guy @Eddypgil is just a gullible loser. Wake up they need to dilute, they have no money, and revenue continues to fall and miss expectations quarter after quarter. Ticker $STXS is in the dictionary next to the phrase dead money

1 · Reply

jb06000 May. 13 at 10:05 AM

$STXS Barely any sale of Magic for first trimester. We should should see invrease in revenue and profit.

6 · Reply

TonySoprano1987 May. 13 at 7:39 AM

$STXS tell me its dead money without telling me its dead money

1 · Reply

jacksonjohn750 May. 13 at 7:05 AM

$STXS don't let this clown keep getting away with his crap.. hold him accountable.. If everone call him out on it... then he can post without his posts being seen.

2 · Reply

Georges8792 May. 13 at 6:49 AM

$STXS david is like donald … problems with ice -> attack iran … problems with catheter production -> buy robocath … maybe has a great vision but we also need execution and execution we need today not in 2 or 3 years

0 · Reply

brunoq14 May. 13 at 2:18 AM

$STXS If Q3 has revenue better than, or at least in the general vicinity of $10M, where will the pps be? You've got to wait until March to add Q4.

1 · Reply

Daquanladariusblackman3 May. 12 at 10:50 PM

$STXS oiii Eddy wya chud

0 · Reply

Daquanladariusblackman3 May. 12 at 10:22 PM

$STXS

1 · Reply

alexpitti May. 12 at 9:47 PM

very exciting report for $STXS don't worry about recurring sales in Q1, none of the magic catheters were produced in the first 2 months. once they were produced in march, those sales went into Q2 placements are coming for GenesisX probably next quarter

1 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-stereotaxis-inc-stock/ $STXS Stereotaxis Earnings Transcript

0 · Reply

Market Cap	189.11M
Revenue (ttm)	32.38M
Net Income (ttm)	-21.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-66.83%
Debt to Equity Ratio	0.00

Volume	364,800
Avg Vol	419,032
Day's Range	N/A - N/A
Shares Out	97.48M
Stochastic %K	25%
Beta	1.34
Analysts	Strong Sell
Price Target	$4.12